Purified fish oils could help treat rare disease affecting newborn babies

A rare and potentially lethal disease of newborn babies whose bodies make too much insulin may be treatable with fish oils, according to researchers from The University of Manchester.

The disease, called congenital hyperinsulinism, means that the infant's brain is starved of blood sugar which can lead to brain damage or long-term disability. But by giving the children purified fish oils similar to those used to treat some , alongside standard medical treatment, their improve, the researchers reported today in the open-access journal Frontiers in Endocrinology.

Congenital hyperinsulinism - the clinical opposite of diabetes - is a rare disorder affecting roughly 1 in 50,000 children overall in the UK. It causes the child's body to produce too much insulin, leading to frequent episodes.

Low blood sugar in the baby's developing brain can lead to long term disabilities or , according to previous research carried out by the team.

Dr Karen Cosgrove, from the University's Faculty of Life Sciences who helped to carry out the new study, says: "Although we didn't see enormous changes in our patients during the research, the effects were small but positive. It is important for all babies with congenital hyperinsulinism because it is a condition which is so difficult to treat."

Researchers from The University of Manchester along with consultants from the Royal Manchester Children's Hospital part of Central Manchester University Hospitals NHS Foundation Trust, teamed up for the research. Royal Manchester Children's Hospital is the base for the Northern Congenital Hyperinsulinism (NorCHI) service which is a highly specialised service for the treatment of this condition.

"Our findings are paving the way for further research into how newer treatments can help to stabilise levels in babies with congenital hyperinsulinism" says Dr Mars Skae, Consultant in Paediatric Endocrinology at Royal Manchester Children's Hospital – and key member of the NorCHI team.

"The current medical treatment for children with congenital hyperinsulinism has been quite limited. The addition of this supplement may be a simple but effective way of treating low blood sugars in many children with this difficult condition" says Doctor Indi Banerjee, Consultant in Paediatric Endocrinology at Royal Manchester Children's Hospital and clinical lead for NORCHI.

More information: 'Reduced glycaemic variability in diazoxide-responsive children with congenital hyperinsulinism using supplemental omega-3-polyunsaturated fatty acids; a pilot trial with MaxEPA' by Mars Skae, Hima Bindu Avatapalle, Indraneel (Indi) Banerjee, Lindsey Rigby, Andy Vail, Peter Foster, Christiana Charalambous, Louise Bowden, Raja Padidela, Leena Patel, Sarah Ehtisham, Karen Cosgrove, Mark Dunne and Peter Clayton. journal.frontiersin.org/Journa… .2014.00031/abstract

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Student seeks to improve pneumonia vaccines

4 hours ago

Almost a million Americans fall ill with pneumonia each year. Nearly half of these cases require hospitalization, and 5-7 percent are fatal. Current vaccines provide protection against some strains of the ...

Seabed solution for cold sores

6 hours ago

The blue blood of abalone, a seabed delicacy could be used to combat common cold sores and related herpes virus following breakthrough research at the University of Sydney.

Better living through mitochondrial derived vesicles

Aug 19, 2014

(Medical Xpress)—As principal transformers of bacteria, organelles, synapses, and cells, vesicles might be said to be the stuff of life. One need look no further than the rapid rise to prominence of The ...

Zebrafish help to unravel Alzheimer's disease

Aug 19, 2014

New fundamental knowledge about the regulation of stem cells in the nerve tissue of zebrafish embryos results in surprising insights into neurodegenerative disease processes in the human brain. A new study by scientists at ...

Engineering new bone growth

Aug 19, 2014

MIT chemical engineers have devised a new implantable tissue scaffold coated with bone growth factors that are released slowly over a few weeks. When applied to bone injuries or defects, this coated scaffold ...

User comments